Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples